| Assembly Biosciences is a clinical-stage biotechnology company. Co. is developing two programs: a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection and a class of oral live microbial biotherapeutic candidates, which are designed to treat disorders related with the microbiome. Co.'s lead HBV core inhibitor product candidate is ABI-H0731. ABI-H2158, its second product candidate in the HBV Cure program. ABI-H3733 is Co.'s third product candidate in the HBV Cure program. Co. has started a clinical study of ABI-M201 to evaluate the safety and its effects on disease activity measures in patients with mildly to moderately active ulcerative colitis. We show 26 historical shares outstanding datapoints in our ASMB shares outstanding history coverage, used to compute ASMB market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ASMB market cap history over the course of time is important for investors
interested in comparing ASMB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ASMB versus a peer is one thing; comparing
ASMB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ASMB can fluctuate over the course of history.
With this page we aim to empower investors researching ASMB by allowing them to research the ASMB market cap history.